生长抑素受体和雌孕激素受体在子宫内膜癌的表达及临床意义

Expression of Somatostatin Receptor, Estrogen and Progesterone Receptor in Human Endometrial Cancer

目的研究生长抑素受体(SSTR)在子宫内膜癌中的表达及其意义;探讨SSTR表达与雌激素受体(ER)、孕激素受体(PR)表达的关系及意义。方法采用免疫组织化学染色方法(SP法)检测60例子宫内膜癌组织中SSTR各亚型及ER、PR的表达情况,分析SSTR各亚型的表达与ER、PR表达的关系。结果在60例子宫内膜癌组织中,SSTR各亚型(SSTR1、SSTR2、SSTR3、SSTR4及SSTR5)的阳性表达率分别为70%,15%,21.7%,23.3%及18.3%;ER、PR的阳性表达率分别为46.7%,70%。SSTR3、SSTR4在中高分化组表达阳性率明显高于低分化组(P<0.05);SSTR各亚型表达与患者年龄、手术病理分期、组织分级及肌层浸润深度无显著相关(P>0.05);SSTR2、SSTR4的表达与ER的表达显著相关(P<0.05),SSTR3、SSTR5的表达与PR表达显著相关(P<0.05)。结论在子宫内膜癌中存在着SSTR各亚型的表达,一些亚型的表达与ER或PR的表达相关,相应的生长抑素类似物(SSTA)可能为SSTR阳性表达的子宫内膜癌的诊治及预后判定提供新的靶点,对孕激素有效的子宫内膜癌,SSTA也可能具有治疗作用。

Objective To study the expression of somatostatin receptor（SSTR） in human endometrial carcinomas and its significance and relationship between the expression of SSTR and estrogen, progesterone receptor （ER, PR） expression. Methods SSTR was detected by immunohistochemical staining, ER and PR was detected by the standard streptavidin-peroxidase（SP） technique. The relationships between SSTR expression and ER, PR expression were analyzed. Results The positive rate of SSTR in 60 endometrial cancers was SSTR1 70%, SSTR2 15%, SSTR3 21.7%, SSTR4 23.3%, SSTR5 18.3% respectively. ER and PR positive rates were 46.7% and 70% respectively. The expression of somatostatin receptor subtypes was independent of age, tumor stage, histological grade and tumor depth except that the expression of SSTR3, SSTR4 in middle to well differentiated group was significantly higher than that in poorly differentiated group（P〈0. 05）. SSTR2, SSTR4 expression was correlated significantly with ER expression（P〈0.05）, while SSTR3, SSTR5 expression was correlated significantly with PR expression（P 〈0.05）. Conclusion Positive expression of SSTR was prevalent in human endometrial cancers. The expression of SSTR3 and SSTR4 was correlated with ER expression, while the expression of SSTR2 and SSTR4 was correlated with PR expression. A subgroup of receptor-positive endometrial cancers may be a potential target for treatment with somatostatin receptor subtype analogs（SSTA）.